<DOC>
	<DOCNO>NCT01513850</DOCNO>
	<brief_summary>The purpose study Evaluate efficacy safety Hepabulin IV ( HBIG , study drug ) liver transplantation .</brief_summary>
	<brief_title>A Confirmatory Study Hepabulin IV HBsAg Positive Liver Transplantation Recipients</brief_title>
	<detailed_description>A 52-week , Multi-center , Open label , Single arm , Phase 3 Study Evaluate Efficacy Safety Hepabulin IV HBsAg positive Liver Transplantation recipient</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>HBsAg Positive candidate HBVrelated liver transplant Primary , single organ recipient write informed consent acute renal failure , Serum creatinin &gt; 1.5*ULN severe cardiac disease significant disease HAV , HCV HIV positive Immunoglobulin A deficiency . History hypersensitivity Human Immunoglobulin . History cancer within 5 year . ( without HCC ) History alcohol or/and drug abuse . History organ transplantation . Within 30 day , participation another clinical trial use investigational product . Subject suffer acute chronic medical , surgical psychiatric condition laboratory abnormality , may increase risk associate study participation investigational product administration , may interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>HBV</keyword>
	<keyword>HBV Recurrence</keyword>
	<keyword>HBsAg Positive</keyword>
</DOC>